Xylem (XYL) announced that its Board of Directors has authorized a new share repurchase program of its common stock of up to $1.5 billion, effective immediately. Repurchases may be made from time to time on the open market or in privately negotiated transactions. “This authorization underscores our confidence in Xylem’s strategy and our ability to generate strong, sustainable cash flow,” said Matthew Pine, Xylem’s president and CEO. “We remain committed to a balanced approach to capital allocation: investing in organic and inorganic growth while opportunistically returning capital to shareholders in a disciplined manner that supports long-term value creation.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XYL:
- Balancing Near-Term Execution Risks and Long-Term Portfolio Upside: Why Xylem Remains a Hold
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 22
- Xylem price target lowered to $155 from $168 at UBS
- Xylem price target lowered to $165 from $170 at Oppenheimer
- Xylem price target lowered to $158 from $175 at Goldman Sachs
